Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion Gets Early Benefits From Savings Plan, Awaits Opsumit Decision

This article was originally published in The Pink Sheet Daily

Executive Summary

With a cost-saving initiative boosting earnings now rather than in 2014 there may be even greater pressure on Actelion’s next-generation PAH therapy – which has a PDUFA date of Oct. 19 – to replace the Swiss company’s aging top-selling product, Tracleer.

Advertisement

Related Content

Actelion Braces For Tracleer Patent Cliff With New Drugs, New Data Standards
European Pharma In Cost-Cutting Mode: Actelion Axes 135 Positions, Sanofi Aims At French R&D Consolidation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel